PanTera Raises $104.1 Million to Expand Radioisotope Production
Deal News | Nov 28, 2024 | Oaklins Evelyn Partners
PanTera, a Belgian producer of radioisotopes and a joint venture between IBA and SCK CEN, has raised $104.1 million in a Series A round led by EQT Life Sciences, with additional equity and debt funding bringing the total to $150 million. The oversubscribed fundraising effort aimed at facilitating the large-scale production of Actinium-225—a key radioisotope for innovative cancer treatment. The capital will be used primarily to construct a cutting-edge production facility in Belgium to mass-produce Actinium-225 and advance theranostics in cancer treatment. Oaklins KBC Securities acted as the sole financial advisor for the transaction, leveraging their expertise in navigating Series A processes, marketing, and closing deals in the life sciences sector. This marks Belgium's largest Series A in life sciences, emphasizing Oaklins' prowess in financial advisory and EQT Life Sciences' commitment to healthcare investment.
Sectors
- Biotechnology
- Healthcare
- Finance
Geography
- Belgium – PanTera is based in Belgium, and the new production facility for Actinium-225 will also be located there, marking it an important geographical focus for the article.
Industry
- Biotechnology – The article is centered around PanTera, a company involved in the production of radioisotopes used in innovative cancer therapies, which is a core aspect of the biotechnology industry.
- Healthcare – PanTera's focus on producing radioisotopes for cancer therapy fits within the healthcare sector, particularly in advancing medical treatments and diagnostics.
- Finance – The article involves a significant fundraising event in the form of a Series A round, engaging various private equity and venture capital firms, which is relevant to the finance industry.
Financials
- $104.1 million – The amount raised during PanTera's Series A fundraising round led by EQT Life Sciences.
- $150 million – The total amount raised including additional equity and debt funding.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| PanTera | Target company | Company | A Belgian radioisotope producer and joint venture aiming to produce Actinium-225 for cancer treatment. |
| EQT Life Sciences | Lead Investor | Company | A leading global healthcare investor that led the Series A round for PanTera. |
| Kurma Partners | Investor | Company | Part of the group of investors in the Series A round for PanTera. |
| Eurazeo | Investor | Company | Another firm participating in the Series A fundraising for PanTera. |
| Korys | Investor | Company | Involved as an equity partner in PanTera's Series A fundraising. |
| Paladin | Investor | Company | Participated in the Series A funding round for PanTera. |
| PMV | Investor | Company | Took part in the investment round, contributing to PanTera's goals. |
| Oaklins Evelyn Partners | Financial Advisor | Company | Advised PanTera on the Series A fundraising transaction. |